Headquartered in Menlo Park, CA Fiscal year ends December NASDAQ: PACB pacb.com
Pacific Biosciences of California (PacBio) is a life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. The company's products and technologies primarily consist of HiFi long-read sequencing systems, including the Revio and Vega platforms, which address applications across human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging areas. PacBio's SPRQ-Nx chemistry enables whole genome sequencing at $345 per genome with enhanced methylation detection and DeepConsensus, an AI-powered consensus algorithm co-developed with Google. The company serves research institutions, clinical laboratories, and population-scale genomics programs globally, and is expanding its focus toward clinical and diagnostics markets as well as AI-related sequencing solutions and databases. PacBio products are currently provided for Research Use Only. Updated
Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not…
Have you thought about adding penny stocks to your portfolio? You may be onto something. That is, as long as you choose the right stock picks. But there are risks to consider too.…
With a market rotation underway, where should investors seeking opportunities in health care be looking? Analysts have high expectations for Alphatec.
These companies all had initial public offerings in 2010 and are still public. Their performance since then has ranged from −97% to over 16,000%.
Pacific Biosciences of California (PacBio) is a life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.
The Wall Street consensus 12-month price target for PACB is $2.16.
